%0 Journal Article
%A Duell, Eric J
%A Lujan-Barroso, Leila
%A Sala, Núria
%A Deitz McElyea, Samantha
%A Overvad, Kim
%A Tjonneland, Anne
%A Olsen, Anja
%A Weiderpass, Elisabete
%A Busund, Lill-Tove
%A Moi, Line
%A Muller, David
%A Vineis, Paolo
%A Aune, Dagfinn
%A Matullo, Giuseppe
%A Naccarati, Alessio
%A Panico, Salvatore
%A Tagliabue, Giovanna
%A Tumino, Rosario
%A Palli, Domenico
%A Kaaks, Rudolf
%A Katzke, Verena A
%A Boeing, Heiner
%A Bueno-de-Mesquita, H B As
%A Peeters, Petra H
%A Trichopoulou, Antonia
%A Lagiou, Pagona
%A Kotanidou, Anastasia
%A Travis, Ruth C
%A Wareham, Nick
%A Khaw, Kay-Tee
%A Ramon Quiros, Jose
%A Rodríguez-Barranco, Miguel
%A Dorronsoro, Miren
%A Chirlaque, María-Dolores
%A Ardanaz, Eva
%A Severi, Gianluca
%A Boutron-Ruault, Marie-Christine
%A Rebours, Vinciane
%A Brennan, Paul
%A Gunter, Marc
%A Scelo, Ghislaine
%A Cote, Greg
%A Sherman, Stuart
%A Korc, Murray
%T Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
%D 2017
%U http://hdl.handle.net/10668/11237
%X Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values
%K biomarkers
%K cohort studies
%K microRNAs
%K pancreatic cancer
%~